KRAS is one of the most frequently mutated oncogenes in human cancer. Despite more than three decades of research, indirect approaches targeting KRAS-mutant cancers have largely failed to show clinical benefit, and direct approaches have been stymied by the apparently ‘undruggable’ nature of KRAS.
To complete your registration, you will be asked to log in using your ACS ID. If you are not already logged in, you may enter your credentials or create an ID from the next screen.Log in or Register Now
This ACS Webinar has ended.
Registrants of this webinar will receive an email with the opportunity to download the slides and view the unedited recording for a 24 hour period after which it will be removed, edited, and become an ACS member benefit.
During this free interactive broadcast, join Brian Lanman of Amgen as he outlines the strategies used to overcome these challenges, the screening approaches employed to identify starting points for these efforts, and the optimization challenges overcome in the identification sotorasib, the first direct KRAS G12C therapeutic to enter human clinical testing.
What You Will Learn
- Why identifying a direct inhibitor of KRAS has proven so challenging
- How covalent inhibition helped to turn KRAS G12C into a tractable target
- What hurdles were overcome in turning initial KRAS G12C binders into potential human therapeutics
- Thursday, February 25, 2021 @ 2-3:30pm ET
- Free to attend with the creation of an ACS ID
- Slides will be available to download on the day of the broadcast